NMD4C Launch Canadian Neuromuscular Clinical Trial Network

The Neuromuscular Disease Network for Canada is thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work. Led by investigators Dr. Craig Campbell, Dr. Jean Mah, and Dr. Kerri Schellenberg, the CTN will work towards increasing the number of neuromuscular clinical trials conducted in Canada, enhancing Canadian neuromuscular trial capacity, and supporting a cohesive network of clinician researchers and their teams.  

Increasing the number of neuromuscular clinical trials conducted in Canada 

The CTN will facilitate connections between industry and clinical sites to support the activation of new clinical trials or the opening of new clinical trial sites. We will deliver information about upcoming neuromuscular trial opportunities and offer information on existing trials available and implement strategic promotion to increase international visibility of the benefits of conducting neuromuscular clinical trials in Canada. 

Enhancing trial capacity 

The CTN will offer education and training programs to clinicians and their teams to improve clinical trial execution, connect with existing patient organizations to increase opportunities for patients to participate in neuromuscular clinical trials, and gather patient feedback from patient organizations and clinical sites to advance the development of patient-centric clinical trials. 

Supporting a network of clinician researchers and their teams 

The CTN will facilitate peer-to-peer mentorship opportunities among trialists specializing in neuromuscular clinical trials, coordinate a pan-Canadian hub for trialists and their teams to discuss clinical trial experiences, and launch a Canada-wide community of practice program for clinical trial coordinators overseeing neuromuscular clinical trials. 

The CTN leadership group will be supported by Maria Masnata, our new clinical trials and community of practice manager. Learn more about the CTN mission and objectives, or contact Maria Masnata for more information! 

NMD4C logo with text reading 'Canadian neuromuscular clinical trials network', MDC and IMHA logos at bottom.

Read next...

NMD4C Talent Pool

Discover Neuromuscular Talent Across Canada

The NMD4C Neuromuscular Talent Pool is now live with new trainees! We invite supervisors and research groups to explore the Talent Pool to identify candidates whose skills, experience, and interests align with your work and upcoming positions. Trainees interested in being included in the Neuromuscular Talent Pool can register by completing the short form, uploading a CV and brief personal statement outlining their experience, interests, and career goals. For more information and to access the Talent Pool, please visit our website.

2026 NMD4C Annual Meeting Registration is Open

Join Us at the 2026 NMD4C Annual Meeting on 25 September

The 2026 NMD4C Annual Meeting will take place in Calgary on Friday, September 25, 2026. The agenda will feature a brief network update, trainee and early-career recognitions, flash talks, a health economics research showcase, and a series of cross‑disciplinary and parallel clinical/pre‑clinical discussion sessions to explore key topics, including advocacy and therapy access, strategies to sustain and strengthen pre-clinical programs, and network sustainability and strategic planning.

BSTC Icon - Light Background

Introducing Our New SOP on Skeletal Muscle Fiber Typing

We are excited to announce the release of our latest Standard Operating Procedure (SOP) titled “Skeletal Muscle Fiber Typing & Cross-Sectional Area Analysis using Immunofluorescence Staining for Mice,” developed by from our Basic Science Trainee Committee (BSTC) member Shatha Atieh, Phd Student at uOttawa. This SOP aims to provide a comprehensive, step-by-step protocol for staining and analyzing skeletal muscle fibers from any muscle group in various mouse models. This new SOP provides detailed methods for immunofluorescence‑based fiber typing using MyHC‑I, MyHC‑IIA, MyHC‑IIB, and laminin, enabling accurate assessment of fiber‑type composition and cross‑sectional area (CSA).